MULTIPLE SCLEROSIS: WHERE DO WE GO FROM HERE?

*Marta Tejera-Alhambra,1 Lidia Fernández-Paredes,2 Clara de Andrés,3 Silvia Sánchez-Ramón2

1. Medical Department, Inmunotek, S.L., Madrid, Spain
2. Department of Clinical Immunology, Hospital Clínico San Carlos, Madrid, Spain
3. Department of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

*Correspondence to tejeramarta@hotmail.com

Disclosure: The authors have declared no conflicts of interest.

Received: 07.01.16 Accepted: 05.04.16

Citation: EMJ Neurol. 2016;4[1]:84-95.

ABSTRACT

Multiple sclerosis (MS) is the most common cause of neurological disability in young populations after trauma and represents a significant personal, social, and economic public health burden. The clinical course and response of MS to therapy is highly heterogeneous, but most patients progress from a relapsing-remitting disease course, in which patients may respond to immunomodulatory drugs, to a steady progression and neurodegeneration that is unresponsive to any currently available treatment. In the last few years, novel disease-modifying therapies for MS have become available but the aetiology of the disease remains an enigma. The search for clinical biomarkers that are able to stratify MS patients and allow the personalisation of treatment strategies, has developed greatly in recent years though only a few have been integrated into routine clinical practice.

Keywords: Multiple sclerosis (MS), biomarkers, clinical activity.

HISTORICAL PERSPECTIVE OF MULTIPLE SCLEROSIS

The first description of multiple sclerosis (MS) dates back to the 14th Century, but it was not until the 19th Century that the first anatomopathological descriptions were made. In 1838, the first report associating the presence of demyelinating lesions with clinical features was published. This discovery was published following an 1835 report of clinical findings, which would subsequently become associated with MS, in a patient who later developed demyelination.1 Some decades later, in 1868, the French pathologist and founder of modern neurology Jean-Martin Charcot formally described the disease entity as ‘sclérose en plaques’ and first detailed the correlation between clinical and post mortem findings.1 By 1955, descriptions of the disease had expanded, due to the discovery of the ‘disseminated’ expansion of lesions in the central nervous system (CNS), and due to the ‘multiple’ lesions and episodes of neurological dysfunction.1 While the French still conserve the original name given by Charcot, the most commonly used label for the disease is multiple sclerosis. Thomas Rivers was the first to induce experimental autoimmune encephalomyelitis (EAE), the animal model of MS; in 1933, Rivers repeatedly injected brain emulsions and extracts from rabbits into primates, inducing the development of CNS demyelinating lesions. This finding, an immune response in the CNS myelin of mammals, suggested an autoimmune aetiology, with a mechanism of injury relating to chronic inflammation as a result of the presence of self-antigens. In 1948, Elvin Kabat described ‘increments’ in the oligoclonal immunoglobulins (Ig) within the cerebrospinal fluid (CSF) of patients with MS, sustaining a local inflammatory nature of the disease.2 The aetiology of MS remains elusive, though several immunomodulatory disease-modifying therapies (DMTs) have shown efficacy in altering the course of the relapsing form of MS, and delaying neurological deterioration, although the mechanisms of action of these drugs are not fully understood. Unfortunately, there is still no effective therapy for the progressive forms of MS.
Epidemiology of Multiple Sclerosis

MS can be defined as a chronic inflammatory demyelinating disease of the CNS in which repeated episodes result in the formation of persistently demyelinated plaques of glial scar tissue, associated with varying degrees of axonal loss. Anatomopathologically, it is characterised by the loss and disruption of the myelin sheath that surrounds the axons in the brain and spinal cord, producing multifocal lesions in the CNS white matter, which can lead to axonal degeneration and progressive neurological dysfunction. Common symptoms include visual disturbances, loss of balance and co-ordination, spasticity, sensory disturbances, bladder and bowel incontinence, pain, weakness, fatigue, and paralysis. MS therefore severely compromises the quality of life of the patient and their family and has a large adverse socioeconomic impact on MS patients, their families, and society as a whole.

Incidence and Prevalence

MS is the most common neurological disease that causes disability in young adults. The disease has an increasing prevalence worldwide, which may be attributable to environmental factors or to increasing awareness and more accurate diagnosis. According to the Atlas of MS, updated in 2013 by the Multiple Sclerosis International Federation, the number of people with MS has increased from 2.1 million in 2008 to 2.3 million in 2013. The median estimated prevalence worldwide is 33 per 100,000 inhabitants, and median estimated incidence is 2.5 per 100,000 inhabitants. Prevalence varies greatly; North America and Europe have the highest prevalence with 140 and 108 per 100,000, respectively, whereas in Sub-Saharan Africa and East Asia the figures are 2.1 and 2.2 per 100,000, respectively. Data from this atlas generally confirm the observation by John Kurtzke in 1975, stating that MS prevalence increases the further a country is from the equator. A North-to-South gradient of declining prevalence of MS seems to be present in Europe, but there are several exceptions to this rule. For instance, Southern European countries like Spain and Italy have recently seen an increase in MS prevalence (>100 per 100,000).

Age of Onset and Sexual Dimorphism in Multiple Sclerosis

Although the age of onset varies widely within the disease, clinical manifestations normally start at childbearing age, ~30 years of age. Children can also suffer from MS; ~3% of MS patients experience their first symptom prior to age 18 years.

As observed in other autoimmune diseases, MS more frequently affects young women than men (ratio 2:1). This female predominance is thought to be due to environmental rather than genetic factors. Potential factors underlying the sex-bias in MS are the effects of sex hormones on immune responses and the differential distribution of sex hormone receptors in immune cell subsets. Interestingly, the disease course of MS is modified by pregnancy and decreases after menopause. During pregnancy the frequency of MS relapses clearly decreases, with a subsequent surge postpartum.

Natural History of Multiple Sclerosis

Clinical Course

MS is a clinically heterogeneous disease, which varies according to the location of plaques in the CNS. Eighty percent of MS patients present with an acute attack, known as clinically isolated syndrome (CIS), which can affect one or several CNS sites. The most commonly affected sites in CIS include the optic nerve, spinal cord, brainstem, and cerebellum; in some rare cases the cerebral hemisphere may be affected. Thus, the most common symptoms include unilateral optic neuritis with visual disturbances; with paraesthesias in the extremities, and weakness in the feet or hands reflecting sensory and motor dysfunction of the spinal cord, respectively. When white matter lesions are detected by magnetic resonance imaging (MRI), the risk of suffering a second relapse increases. New attacks occur with different frequencies, but on average rarely exceed 1.5 episodes per year. Most patients with CIS develop relapsing–remitting multiple sclerosis (RRMS) within 5 years of onset, and a majority of patients with RRMS (~65%) develop secondary progressive multiple sclerosis (SPMS) after a median of 10–15 years from disease onset. RRMS is characterised by recurrent relapses with total or partial recovery and an inflammatory course that can be modified with therapy. Around 20% of patients have a progressive onset...
without relapses, known as primary progressive multiple sclerosis (PPMS). Some MS patients present a milder form of the disease and are defined as ‘benign MS’ patients. Due to the difficulty in predicting disease progression, it takes decades after the initial diagnosis to know if a course is benign. The term ‘benign MS’ is somewhat controversial since it has classically been based mainly on changes in motor functions. These patients may have normal employment and domestic activities for some decades, however studies have shown that over a number of years, their cognitive function deteriorates and they suffer fatigue, pain, and depression that negatively impacts their quality of life.

RRMS and PPMS show different clinical courses. RRMS patients traditionally display a ‘two-stage’ disease: a first stage in which there is a predominance of inflammation (relapses and remissions) compared with SPMS, and a second stage with predominant neurodegeneration and progression (demyelination and axonal loss). However, this classical timeline view is no longer so clearly demarcated, as neuroimaging studies have shown the coexistence of inflammation and neurodegeneration from the onset of the disease. In addition, recent studies indicate that inflammation is abundant in PPMS and correlates with axonal damage and disease progression, involving follicular T helper (Th) cells, Th17, and activated B cells. The presence of meningeal inflammation is associated with an increased rate of clinical progression in PPMS.

Therapeutic strategies differ depending on the target phase of the disease: immunomodulatory therapies combat inflammation in the inflammatory phase and neuroprotective agents fight against myelin/neural degeneration in the progressive phase. By contrast, PPMS patients present with a steady progression and degeneration from the onset of disease.

Acute inflammation occurs during relapses with partial or complete remyelination during remissions, but progressive neurodegeneration leads to a higher brain volume loss and clinical disability. For the SPMS and PPMS clinical forms, treatments available to date are unable to stop the progression of the disease.

Prognosis

A review of large long-term studies in MS has identified different prognostic factors associated with MS disability and progression. For RRMS patients, negative prognostic factors identified were a higher initial relapse rate, a shorter interval to the second relapse, a higher level of disability in the first 5 years, and the involvement of more systems. A shorter time-to-progression is typical in SPMS, while PPMS demonstrates a faster rate to disability in the first 2 and 5 years and the involvement of more than three systems. The presence of these prognostic factors does not necessarily imply disability as there is a large variability in patient outcomes. A recent study by Tintore et al. that included 1,015 CIS patients with a mean follow-up of 6.8 years, identified that the number of lesions (≥10) detected by MRI and the presence of oligoclonal bands (OCB) are prognostic factors for the development of MS and early disability.

The life expectancy and prognosis for MS patients is highly variable. Recently a large study identified that life expectancy is reduced by 7 years in MS patients compared with matched healthy controls, and that mortality from both infectious diseases and diseases of the respiratory system is higher in MS patients. The symptoms of MS are lifelong, painful, and debilitating; the treatment and prevention of comorbidities in MS should therefore be considered in the management of these patients to improve their condition, survival, and quality of life.

AETIOPATHOLOGY

The aetiology of MS is still unresolved. A number of theories have been proposed as to the nature of the disease, including origins of autoimmune, infectious, genetic, metabolic, dietary, or neurodegenerative nature. None of these hypotheses alone can explain the clinical heterogeneity of the disease, therefore it is more probable that all of these factors contribute to the generation and maintenance of the disease to some extent. The major aetiopathogenic factors known to be involved in MS disease are summarised in Figure 1 and Table 1. MS is currently considered a complex disorder, which is triggered in genetically susceptible individuals by different environmental and stochastic factors. Environmental factors, such as vitamin D levels, excessive hygiene during childhood, and neurotropic viruses have all previously been widely associated with MS aetiology. Different pieces of evidence suggest that the disease might be
triggered by an infectious agent and evolve into an immune-mediated chronic disease, however to date no virus has been isolated or directly linked with MS.

The immune system also plays an important role in MS pathophysiology. This is supported by diverse facts:

- Susceptibility to MS is linked to important genes of the immune response
- MS lesions are crowded with inflammatory lymphocytes and macrophages
- OCB of Ig are present in the CSF of most MS patients
- Available DMTs target inflammation in the CNS, reducing the number of relapses and lesions detected by MRI, although they are not effective in attenuating the neural damage observed in disease progression

The most accepted theory for MS is that autoreactive T lymphocytes directed against myelin peptides reach the CNS by crossing the blood brain barrier (BBB), and triggering the pathological events that lead to demyelination and axonal damage. This insult to axons can be mild and reversible or severe and irreversible, with transection and likely loss of neuronal function.

The contribution of the target organ, the CNS, has been almost completely ignored in the literature. Pathological and imaging studies, as well as research on the molecular aspects of the disease, in EAE and MS patients, now provide further evidence that CNS-specific factors are important.

In summary, MS is a complex autoimmune disease with multiple intrinsic and extrinsic factors that may trigger autoreactivity to self-antigens in the CNS.

### RISK FACTORS ASSOCIATED WITH MULTIPLE SCLEROSIS

Environmental risk factors include, among others, infections, smoking, and vitamin D status (Table 1). Smoking or exposure to cigarette smoke contributes to both increased disease susceptibility and more rapid disease advancement. The relative risk for MS development is approximately 1.5-times higher for smokers compared with nonsmokers. Epstein–Barr virus (EBV) infection is considered a risk factor for MS; higher rates of EBV infection have been observed in children with MS compared with age-matched controls. Individuals who acquired EBV in adulthood had a 2 to 3-fold higher risk of MS. The geographical distribution of MS also correlates with the duration and intensity of sun exposure; some large longitudinal studies support an inverse association between vitamin D and risk of MS.

### DIAGNOSIS OF MULTIPLE SCLEROSIS

The cornerstone of MS diagnosis is based on clinical evidence from a detailed neurological history and physical examination. Symptoms and signs of disorder in the motor, sensory, visual, and autonomic systems, as well as many others may be observed. The diagnosis of MS relies on the demonstration of disease dissemination in space (at least two independent CNS lesions) and time (two or more episodes of neurological dysfunction separated by at least 30 days).

---

**Figure 1: Factors affecting the development of multiple sclerosis.**

HLA: human leukocyte antigen; IL: interleukin; CNS: central nervous system; MS: multiple sclerosis.
The introduction of Poser criteria for diagnosis divided MS patients in two major groups: ‘definite’ and ‘probable’. These groups are defined by either a clinical or laboratory-supported diagnosis. The criteria also allowed the classification of MS patients according to the number of attacks, clinical and paraclinical evidence, and CSF OCB or increased IgG index. The Poser criteria were developed before MRI scans and were superseded by the McDonald criteria, which underline the importance of MRI in the diagnosis of MS and allow earlier diagnosis of patients with CIS. The McDonald criteria were published in 2001 and were revised in 2005 and 2010. The revision from 2005 included changes focusing on demonstrating dissemination of lesions in time, clarification of the use of spinal cord lesions, and simplification of PPMS diagnosis. The 2010 revision was written with the objective of simplifying and accelerating diagnosis; the criteria relating to use of imaging techniques for demonstrating the dissemination of CNS lesions in space and time was simplified, and the applicability allowed an earlier diagnosis and more uniform use in populations other than Western Caucasian adults.

### Table 1: Aetiopathology of multiple sclerosis.

<table>
<thead>
<tr>
<th>Environmental factors</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Migration</td>
<td>MS development risk is associated with the place of residence in childhood&lt;sup&gt;42&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hygiene hypothesis</td>
<td>Sanitation level of the surrounding environment during childhood may affect the risk of later developing MS&lt;sup&gt;43&lt;/sup&gt; An increase in MS incidence is associated with a reduction in intestinal parasitic infections&lt;sup&gt;44&lt;/sup&gt;</td>
</tr>
<tr>
<td>Neurotropic viruses</td>
<td>HHV-6 is only expressed in the oligodendrocytes from MS plaques&lt;sup&gt;45&lt;/sup&gt; HHV-6 DNA seems to correlate with exacerbations in the RRMS phase&lt;sup&gt;46&lt;/sup&gt; Children with MS with EBV seem to be infected at higher rates than their age-matched controls&lt;sup&gt;47&lt;/sup&gt; Molecular mimicry between myelin basic protein and an EBV peptide may be a pathophysiological mechanism to induce demyelination&lt;sup&gt;48&lt;/sup&gt; IgG against other neurotropic viruses as measles, rubella, and varicella zoster have been reported in the CSF of MS patients&lt;sup&gt;49&lt;/sup&gt;</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>The geographical distribution of MS correlates with the duration and intensity to sun exposure&lt;sup&gt;59&lt;/sup&gt; Large studies have found that taking vitamin D supplements and having high serum levels of 25(OH)D protects against MS&lt;sup&gt;40,41&lt;/sup&gt;</td>
</tr>
<tr>
<td>Genetics</td>
<td></td>
</tr>
<tr>
<td>Familial studies</td>
<td>Twin studies have reported concordance rates of MS of -25% for monozygotic twins and -5% for dizygotic twins&lt;sup&gt;50&lt;/sup&gt; Non-twin-siblings have a 20 to 40-fold increased risk</td>
</tr>
<tr>
<td>MHC II risk alleles</td>
<td>DRB1<em>1501 allele: strongest and most replicated genetic association with MS&lt;sup&gt;51&lt;/sup&gt; Being heterozygous for the DRB1</em>1501 allele increases the risk of MS by 3-fold and homozygosity by over 6-fold&lt;sup&gt;52&lt;/sup&gt; DR3 and DR4 haplotypes: present in Sardinian and other Mediterranean MS patients&lt;sup&gt;53,54&lt;/sup&gt;</td>
</tr>
<tr>
<td>Non-MHC II risk alleles</td>
<td><em>IL-2RA</em>,&lt;sup&gt;55&lt;/sup&gt; <em>CD58</em>,&lt;sup&gt;56&lt;/sup&gt; <em>STAT3</em>,&lt;sup&gt;57&lt;/sup&gt; <em>IL-7RA</em>&lt;sup&gt;58&lt;/sup&gt;</td>
</tr>
<tr>
<td>Immunoregulatory defects</td>
<td></td>
</tr>
<tr>
<td>Treg cells</td>
<td>Defective suppressive function of Treg cells&lt;sup&gt;59&lt;/sup&gt; Natural Treg cell thymic output is diminished compared to that of healthy controls&lt;sup&gt;59,60&lt;/sup&gt; Decreased expression of FoxP3 levels in Treg cells from MS patients, with decreased function&lt;sup&gt;61&lt;/sup&gt;</td>
</tr>
<tr>
<td>Oligoclonal B cell activation</td>
<td>B cells abnormally activated in meningeal follicles differentiate to plasma cells that produce intrathecal immunoglobulins detected as OCB in most MS patients&lt;sup&gt;62&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Clinical

The cornerstone of the MS diagnosis continues to be based on clinical evidence from a detailed neurological history and physical examination, but paraclinical tests are useful in establishing an accurate MS diagnosis. Some symptoms and signs of dysfunction to the motor, sensory, visual, and autonomic systems can be observed, but many others can occur.

There are two characteristic clinical symptoms of MS: Lhermitte’s sign (electrical sensation that runs down the spine or limbs on neck flexion) and Uhthoff’s phenomenon (transient worsening of symptoms when the body temperature increases, for instance following exercise or a hot bath). Although these symptoms are considered MS-specific they may be present in other diseases. Because MS shares clinical manifestations with other conditions, the differential diagnosis and exclusion of other diseases is an integral part of MS diagnosis.

Paraclinical features can help establish diagnosis.

Magnetic Resonance Imaging

MRI is one of the main tools for supporting and accelerating MS diagnosis due to its availability and sensitivity. White matter abnormalities are characteristic and demonstrated in >95% of MS patients. MRI shows the anatomical dissemination of lesions and if used serially over time, can highlight newly developed plaques in the absence of clinical episodes.

MRI provides information about the histopathology of MS lesions. The pathological hallmark of MS is focal demyelination in the lesions, with variable degrees of inflammation, demyelination, gliosis, and axonal injury. The site of the lesion is very important for MS diagnosis, as MS lesions are commonly located in the brainstem, spinal cord, cerebellum, and periventricular white matter. Typical MRI protocols include T1-weighted (T1) imaging with and without gadolinium (Gd) administration, T2-weighted (T2 imaging), proton-density (PD), diffusion-weighted imaging and calculation of the apparent diffusion coefficient, in which active plaques may demonstrate restricted diffusion, and fluid-attenuated inversion recovery techniques (FLAIR). In T2 scans lesions are highlighted by hyperintense regions whereas in T1 scans lesions are highlighted by hypointense regions. T2, PD, and FLAIR demonstrate the most severely demyelinated lesions well. In the acute phase, T1 hypointensity reflects oedema and demyelination, which disappears when inflammation attenuates. On the contrary, chronic foci of T1-hypointensity (known as black holes) reflect persistent axonal loss.

Typically, several T2-hyperintense lesions are commonly observed in MS patients; characteristic abnormalities on T2 images occur in >95% of patients with clinically definite MS, and in 50–70% with a CIS. MRI positivity alone cannot provide a correct diagnosis because lesions are not exclusively characteristic of MS disease, and also appear in people without clinical signs of disease and in people >50 years old. However, lesions detected in the spinal cord are abnormal at any age. Gd enhancement in T1 imaging indicates active lesions, inflammation, and evidence of breakdown of the BBB. Cortical atrophy may also be prominent and correlates with cognitive impairment. Active white matter lesions are classified according to the four observable distinct patterns that originate from different pathophysiological mechanisms. Pattern IV lesions, for instance, are found in ~5% of PPMS patients. Some authors have recently stated that patients with one pattern of lesion conserve it throughout their disease course, while others have described a progression from heterogeneity in lesions to homogeneity over the disease course. Despite controversies concerning lesion heterogeneity, it is clear that as the disease progresses, active lesions become fully demyelinated and convert to an inactive morphology. Recent guidelines recommend the use of MRI for prognostic and therapy monitoring tasks.

New MRI techniques such as volumetric MRI and magnetisation transfer ratio (MTR) are now available. Volumetric MRI allows measurement of brain and spinal cord atrophy in MS and progressive atrophy may have potential as a marker of progression in the monitoring of MS patients. MRI cannot effectively detect cortical demyelination in MS patients but recent studies have shown that MTR imaging is sensitive to cortical lesions in these patients.

Cerebrospinal Fluid

A lumbar puncture can be performed to better elucidate the aetiology of a clinical episode. The detection of two or more OCB of IgG in the CSF (and not in the serum of MS patients) is the
most important CSF test finding, and is a red flag in MS diagnosis, as OCB are seen in most patients (>90%).

OCB reflect intrathecal Ig synthesis, however the detection of OCB is not exclusive to MS and has diagnostic value only once other causes of CNS inflammation have been excluded.

Complementary tests are available, such as the IgG index ([IgG (CSF) / IgG (serum)] / [Albumin (CSF) / Albumin (serum)]), which is increased in 80% of patients (ratio >0.7), and measures of cell count (50% with >4 white cells/µL, but only 1% with cell counts >35/µL). These complementary tests are useful in the differential diagnosis of MS.

**Table 2: Actual and promising novel body fluid biomarkers for diagnosis, prognosis, subtyping, and therapeutic response evaluation of multiple sclerosis.**

<table>
<thead>
<tr>
<th>Biomarkers</th>
<th>Source</th>
<th>MS findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnostic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG OCB</td>
<td>CSF</td>
<td>Increased in MS but with low specificity</td>
</tr>
<tr>
<td>IgG index</td>
<td>CSF/Blood</td>
<td>Increased ratio (&gt;0.7) in MS</td>
</tr>
<tr>
<td>MBP-MOG antibodies</td>
<td>Blood</td>
<td>Increased levels in MS patients</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Blood</td>
<td>Decreased levels in MS</td>
</tr>
<tr>
<td>Neurofilament light chain</td>
<td>CSF</td>
<td>Increased levels in MS patients</td>
</tr>
<tr>
<td>Anti-aquaporin-4</td>
<td>Blood</td>
<td>Differential diagnosis: Present in patients affected by NMO, absent in MS</td>
</tr>
<tr>
<td>CSF/serum albumin ratio</td>
<td>CSF/blood</td>
<td>Differential diagnosis: Increased in NMO</td>
</tr>
<tr>
<td>N-acetylaspartate</td>
<td>Blood/CSF</td>
<td>Differential diagnosis: Increased in MS in respect to NMO</td>
</tr>
<tr>
<td><strong>Prognostic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MBP and MOG antibodies</td>
<td>Blood</td>
<td>Increased levels in patients developing MS after the first CIS episode</td>
</tr>
<tr>
<td>Chitinase-3-like protein 1</td>
<td>CSF</td>
<td>Increased levels in patients developing MS after the first CIS episode</td>
</tr>
<tr>
<td>Kappa-free light chains</td>
<td>CSF</td>
<td>Increased levels in patients developing MS after the first CIS episode</td>
</tr>
<tr>
<td>IgM OCB</td>
<td>CSF</td>
<td>Increased levels in patients developing MS after the first CIS episode</td>
</tr>
<tr>
<td>MRZ-specific IgG antiviral antibodies</td>
<td>CSF</td>
<td>Increased levels in patients developing MS after the first CIS episode (higher specificity than IgG OCBs)</td>
</tr>
<tr>
<td>Chemokine ligand 13</td>
<td>CSF</td>
<td>Increased levels in patients developing MS after the first CIS episode, but not specific</td>
</tr>
<tr>
<td>Epstein–Barr virus antibodies</td>
<td>Blood/CSF</td>
<td>Increased specific IgG antibodies in MS patients with an early disease onset</td>
</tr>
<tr>
<td>VEGF-A</td>
<td>Blood monocytes</td>
<td>Diminished mRNA expression in SPMS compared with RRMS</td>
</tr>
<tr>
<td>NO metabolites</td>
<td>CSF</td>
<td>Increments correlate with high disability progression</td>
</tr>
<tr>
<td>Neurofilament heavy chain</td>
<td>CSF</td>
<td>Increased in progressive forms of MS</td>
</tr>
<tr>
<td>Tubulin/actin</td>
<td>CSF</td>
<td>Increased in progressive disease forms</td>
</tr>
<tr>
<td>Glial fibrillary acidic protein</td>
<td>CSF</td>
<td>Increased in SPMS patients with respect to RRMS</td>
</tr>
<tr>
<td>Brain-derived neurotrophic factor</td>
<td>CSF</td>
<td>Decreased in SPMS patients with respect to RRMS</td>
</tr>
</tbody>
</table>
The multiplicity of putative biomarkers, limited information on their independent diagnostic/prognostic value, and the lack of validation in independent patient cohorts are major hurdles for their application in routine clinical practice.

The ideal biomarker for MS should have the following characteristics: 79

- Measures clinically relevant MS outcomes
- Preferably reflects a causal association
- Detected in an easily accessible biological sample with minimal pre-analytical perturbations
- The assay for its identification is simple, affordable, and stable, and can be validated independently

Promising novel body fluid biomarkers for diagnosis, prognosis, MS subtyping, and therapeutic response evaluation have been detailed elsewhere 80 and are summarised in Table 2.

### Multiple Sclerosis Biomarkers Used in Clinical Practice

Currently there is a scarcity of biomarkers that can be used in clinical practice; these are limited to CSF IgG OCB, 81 IgG index, 81 neutralising antibodies against interferon (IFN)-β 82 and natalizumab, 83 varicella zoster virus (VZV) antibodies, 84 anti-John Cunningham virus (JCV) antibodies, 85 and anti-aquaporin-4 (AQP4) antibodies.

### Diagnostic Biomarkers

Detection of two or more CSF IgG OCB in a patient with clinical signs of MS provide very useful diagnostic value. 81 OCB can be detected from disease onset and persist during disease course.

<table>
<thead>
<tr>
<th>Biomarkers</th>
<th>Source</th>
<th>MS findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subtype specific</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-223, miR-23a, miR-15b</td>
<td>Blood</td>
<td>Decreased in PPMS</td>
</tr>
<tr>
<td>HGF, CCL11</td>
<td>Blood</td>
<td>Increased in progressive forms of MS</td>
</tr>
<tr>
<td>EGF, CCL4</td>
<td>Blood</td>
<td>Decreased in progressive forms of MS</td>
</tr>
<tr>
<td>bFGF</td>
<td>Blood</td>
<td>Decreased in PPMS patients</td>
</tr>
<tr>
<td>VEGF</td>
<td>Blood</td>
<td>Increased in SPMS patients</td>
</tr>
<tr>
<td><strong>Therapeutic response</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MBP-MOG antibodies</td>
<td>Blood</td>
<td>Good responders to B cell target therapy</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Blood</td>
<td>Increased in IFN-β responders</td>
</tr>
<tr>
<td>Neurofilament light chain</td>
<td>CSF</td>
<td>Levels raise to normal in natalizumab responders</td>
</tr>
<tr>
<td>Brain-derived neurotrophic factor</td>
<td>Cell culture</td>
<td>Increased levels in glatiramer acetate treated patients</td>
</tr>
<tr>
<td>Neutralising antibodies against IFN-β</td>
<td>Blood</td>
<td>Present in IFN-β non-responders</td>
</tr>
<tr>
<td>Neutralising antibodies against natalizumab</td>
<td>Blood</td>
<td>Present in natalizumab non-responders</td>
</tr>
<tr>
<td>VZV antibodies</td>
<td>Blood</td>
<td>Recurrence risk of infection in previously VZV-infected MS patients receiving fingolimod treatment</td>
</tr>
<tr>
<td>Anti-JCV</td>
<td>Blood</td>
<td>Risk of developing progressive multifocal leukoencephalopathy in patients infected by JCV receiving natalizumab treatment</td>
</tr>
</tbody>
</table>

Ig: immunoglobulin; MRZ: measles, rubella, and varicella zoster viruses; CSF: cerebrospinal fluid; MS: multiple sclerosis; MBP: myelin basic protein; MOG: myelin oligodendrocyte glycoprotein; NMO: neuromyelitis optica; CIS: clinically isolated syndrome; MR2: mouse monoclonal receptor; VEGF-A: vascular endothelial growth factor A; mRNA: messenger RNA; SPMS: secondary progressive multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; NO: nitric oxide; HGF: hepatocyte growth factor; EGF: epidermal growth factor; bFGF: basic fibroblast growth factor; IFN: interferon; VZV: varicella zoster virus; JCV: John Cunningham virus; OCB: oligoclonal band.
regardless of disease activity. An increased IgG index (ratio >0.7, reflecting intrathecal IgG production) supports MS diagnosis but has no effect on clinical decision making.81

AQP4-IgG are highly specific autoantibodies that target the astrocytic water channel AQP4 and are present in the serum of patients with neuromyelitis optica. These antibodies have become the first clinically useful diagnostic biomarker that allows the classification of a subgroup of patients with inflammatory demyelinating disorders that selectively affect the spinal cord and the optic nerves. The prognosis and treatment is different between these diseases,86 making differential diagnosis all the more necessary.

Treatment Response Biomarkers

The presence of IFN-β neutralising antibodies has been found in patients with relapse, and therefore physicians might consider stopping treatment with IFN-β in these cases as it may be ineffective.92 Recent DMTs such as natalizumab and fingolimod (sphingosine 1-phosphate receptor modulator) have shown unexpected fatal adverse reactions. Around 5% of MS patients treated with natalizumab (anti-α4-integrin monoclonal antibody) will develop anti-natalizumab antibodies, which are associated with reduced therapeutic efficacy of natalizumab and infusion-related adverse events.87 Patients on natalizumab are at increased risk for progressive multifocal leukoencephalopathy (PML) caused by reactivation of the JCV.88 This risk for PML can be calculated with an algorithm that includes three risk factors: anti-JCV antibody status, previous use of immunosuppressants, and duration of natalizumab treatment.89 Thus, anti-JCV antibody measurement is a useful biomarker in the stratification of patient risk.85 Patients on oral fingolimod are at increased risk for developing herpetic infections,90 and it is advisable that physicians test for VZV antibodies and consider vaccinating seronegative patients at least 1 month before starting treatment with fingolimod.84

The DMTs available for MS include: injectable treatments with immunomodulatory properties such as IFN-β formulations, glatiramer acetate and mitoxantrone; two monoclonal antibodies: natalizumab (anti-α4-integrin, which inhibits lymphocyte migration through the BBB)91 and alemtuzumab (anti-CD52 with immunosuppressive properties);92 and three oral drugs: fingolimod (an immunosuppressive metabolite that recruits lymphocytes within the lymph organs, inhibiting their migration to the CNS),93 teriflunomide (inhibits de novo synthesis of pyrimidine, preventing clonal expansion of activated lymphocytes),94 and dimethyl fumarate (with immunomodulatory and antioxidative properties).95

Potential Cerebral Spinal Fluid Biomarkers to Support Early Multiple Sclerosis Diagnosis

CSF is the body fluid in direct contact with the CNS, the target organ of MS, and the measurement of biomarkers in the CSF may shed light on the pathological processes occurring. CSF is obtained through an invasive procedure and therefore its collection can only be justified for initial diagnosis, and exceptionally for monitoring the disease. Some CSF biomarkers identifying CIS patients likely to convert to MS have been validated in independent patient cohorts and are closer to clinical implementation. Increased chitinase-3-like protein 1, secreted by activated macrophages, may define those patients with CIS that later convert to clinically definite MS.96 Increased CSF kappa-free light chains, secreted by the plasma cells, might further support MS diagnosis.97 CIS patients with IgM CSF OCB have an increased risk of converting to clinically definite MS and show a more aggressive disease course.98 An intrathecal polyspecific reaction to neurotropic viruses such as measles, rubella, and VZV (MRZ-specific IgG) is associated with an increased risk of conversion to MS.49 Chemokine ligand 13(CXCL13), involved in B cell recruitment to the CNS during inflammation, has a relevant role in B cell activation. CXCL13 levels in MS are increased in CIS ‘converters’ compared with ‘non-converters’,99 although CXCL13 is not specific to MS and appears in other inflammatory or infectious diseases of the CNS.99

Potential Peripheral Blood Biomarkers of Multiple Sclerosis

Peripheral blood biomarkers represent a much less invasive procedure (compared with CSF testing) and their integration, from bench to bedside, would be better for patients and more practical, as these samples can be more easily collected. The number of MS biomarkers in the diagnosis phase is large49,80,89 and beyond the scope of this review. Biomarkers for the differentiation between the progressive (SPMS and PPMS) forms and the RRMS form are still lacking. Recently, it has been shown that the levels of non-coding RNAs, such as serum microRNAs (miRNAs) miR-223,
miR-23a, and miR-15b are decreased in PPMS and are strongly correlated with the Expanded Disability Status Scale. Therefore, they can be considered candidate biomarkers for differentiating PPMS from RRMS.\(^{100}\) Our group recently published a study with two independent observational cohorts of different biomarkers for the classification of MS clinical subtypes. We found that a combination of four plasma proteins: hepatocyte growth factor (HGF), eotaxin, epidermal growth factor (EGF), and macrophage inflammatory protein (MIP)-1β, serve as an effective tool in the clinical subtyping of MS patients. HGF and eotaxin were risk factors for developing a progressive form of MS (SPMS or PPMS), while EGF and MIP-1β were protective factors of progression.\(^{101}\) The combination of these four plasma levels by multivariate logistic regression provided a higher sensitivity and specificity than when the proteins were considered independently. This approach of combining analytes might be clinically useful and its practical application should be replicated and validated in larger cohorts. We also found that plasma fibroblast growth factor levels were decreased in PPMS patients, and that vascular endothelial growth factor was increased in SPMS patients.

**CONCLUSIONS**

MS remains a heterogeneous and complex disease. Despite recent advances in DMTs, the progressive and neurodegenerative forms of the disease remain incurable. The aetiology of MS remains an enigma and there is an urgent need to recognise and predict outcomes in individual MS patients that could enable more personalised treatment strategies. Therefore, the identification and development of targeted therapies and biomarkers has moved to the forefront of MS translational research.

### Acknowledgements

Our acknowledgment to Fundación Mapfre, Fundación Salud 2000, Fondo de Investigación Sanitaria, and the European Research Council Starting Award for their support.

### REFERENCES


